Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Reindl

Is the Proof of an Additional Benefit Under Amnog in Germany More Difficult for Certain Drugs Than for Other Ones?

Value in Health

Occupational Health

English

Related publications

Relationship Between the Price Differences in Orphan Drugs With More Than One Benefit Assessment in Amnog and the Potential Influencing Factors

Value in Health

Occupational Health

English

Php35 - Amnog Early Benefit Assessment (Eba) and Market Penetration of New Drugs for Melanoma, Multiple Sclerosis and Diabetes Mellitus in Germany

Value in Health

Occupational Health

English

Is the Diversification Benefit for Teams More Sustainable Than at the Financial Market?

Wirtschaftsinformatik

Information Systems

English

2.5 Years of Amnog in Germany – An Analysis of Benefit Assessment and Net Price Negotiation Trends

Value in Health

Occupational Health

English

Is the Dalkon Shield More Dangerous Than Other IUCDs?

English

Predicting Post-Amnog Rebate Outcomes for Oncology Drugs

Value in Health

Occupational Health

English

Radical Stress Is More Cytotoxic in the Nucleus Than in Other Organelles

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Points: Is the Dalkon Shield More Dangerous Than Other IUCDs?

English

Editorial: Better Outcomes for Crohn's Disease-More Than Just the Drugs?

Alimentary Pharmacology and Therapeutics

Gastroenterology

English